Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.

Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?

AmerisourceBergen

McKesson

CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas--(BUSINESS WIRE)--AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have reached an agreement with the Washington Attorney General, under which the distributors will pay up to $518 million to the State of Washington and its participating subdivisions to resolve opioid-related claims. This amount is consistent with Washington's allocation under the previously announced comprehensive agree

Distributors Agree to Opioid Settlement With Washington State

DUBLIN, Ohio , April 27, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced the winners and honorees of its annual Lab Excellence List, which names top clinical laboratory professionals making significant contributions to health care and patient outcomes through their research, diagnosis, innovation or advocacy. The list is part of celebrations surrounding the industry's annual Medical Laboratory Professionals Week, a more than 40-year-long tradition that celebrates lab professionals across all of health care.

Cardinal Health honors top clinical laboratory professionals

Atmos Energy

Essex Property Trust

Coca-Cola

Realty Income Corp

Walmart

Exxon Mobil

Even though some early first-quarter earnings have come in very solid, the reality is the market is teetering and could be ready to plunge.

8 ‘Strong Buy' Rated Dividend Aristocrats to Buy Now in Case of a Total Market Collapse

Clorox

These are great places to park your money for the long haul.

Got $5,000? These 2 Aristocrats Are Paying More Than Double the S&P 500 Average

DUBLIN, Ohio , April 1, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2022 on May 5 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Webcast Discussion of Third-Quarter Results for Fiscal Year 2022 on May 5

Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.

Cardinal Health (CAH) to Extend Medical Distribution Presence

DUBLIN, Ohio , March 30, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced plans to build a 574,670 square foot medical distribution center in the Columbus, Ohio area. The new building will integrate automation and technology to work alongside Cardinal Health employees; improve safety, service and quality; deliver operational efficiencies; and better support fluctuations in volume and labor to provide customers with a predictable and stable customer experience.

Cardinal Health expands medical distribution footprint in Ohio

West Pharmaceutical Services

Despite the COVID-19 pandemic-induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

3 Lucrative Stocks From the Promising Dental Supplies Industry

Cardinal Health Remains A Bargain

Cardinal Health's (CAH) introduction of the first surgical incise drape is likely to lower SSIs.

Cardinal Health (CAH) Unveils the First Surgical Incise Drape

The incise drape is the first to feature Avery Dennison's patented BeneHold™ CHG adhesive technology  DUBLIN, Ohio, March 17, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today launched the first surgical incise drape using industry-leading antiseptic Chlorhexidine Gluconate (CHG). The drape features Avery Dennison's patented BeneHold™ CHG adhesive technology, which helps reduce the risk of surgical site contamination with organisms typically associated with surgical site infections (SSIs).

New Cardinal Health surgical drape helps reduce surgical site contamination risk

Con Ed

General Dynamics

Dividend aristocrats are a particularly intriguing area of the market to consider, as investors can rely on these companies for consistent increases in payouts over the years.

3 Dividend Aristocrats to Buy in a Volatile Market

Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Pick Cardinal Health (CAH) Stock Now?

Johnson & Johnson

The U.S. Justice and Treasury Departments should review the tax deductions four drugmakers made related to their $26 billion opioid settlement, the U.S. House Oversight and Reform Committee said in a statement on Monday.

U.S. should review drugmakers' opioid settlement tax breaks - House panel

Amcor Plc

While most of the attention this past week has been focused on the conflict between Ukraine and Russia, the real problem for investors is the mounting inflation pressures that are at the highest levels in over 40 years.

The Bear Market Is Growling: 5 Dividend Aristocrats to Buy Now for Safety and Income

CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas--(BUSINESS WIRE)--AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that each company has independently determined that there is sufficient participation by states and litigating political subdivisions to proceed with a comprehensive agreement to settle the vast majority of the opioid lawsuits filed by state and local governmental entities. The companies have previously disclosed that 46 of 49 eli

Distributors Approve Opioid Settlement Agreement

Chubb

General Electric

GlaxoSmithKline

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Leggett & Platt

Mondelez

Altria

PepsiCo

Philip Morris

With February already underway, it is time for all dividend income investors to look back at the previous month and see how much passive dividend income our portfolios generated.

Dividend Income Update January 2022

Cue Health

SAN DIEGO and DUBLIN, Ohio, Feb. 17, 2022 /PRNewswire/ -- Today Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, and Cardinal Health (NYSE: CAH) announced expanded distribution of Cue's professional use and over-the-counter COVID-19 tests. Cue selected Cardinal Health, which serves nearly 90% of US hospitals and over 60,000 pharmacies, as one of its primary distributors due to a demonstrated expertise in helping commercialize diagnostic technologies.

Cue Health Taps Cardinal Health to Distribute its Pioneering Molecular COVID-19 Tests

Cardinal Health continues its track record of strong revenue growth.

Why Cardinal Health Is A Sound Buy In This Crazy Market

DUBLIN, Ohio, Feb. 10, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) has been recognized by Forbes as one of America's Best Large Employers 2022, a list of more than 500 public and private corporations, hospitals, universities and more, across dozens of industries.    Forbes identified America's Best Employers through an independent survey taken by approximately 60,000 American employees working for U.S. companies that employ more than 1,000 people.

Cardinal Health named one of America's Best Large Employers 2022 by Forbes magazine

DUBLIN, Ohio, Feb. 9, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced it will leverage the Kinaxis® RapidResponse® platform to increase medical product visibility and supply chain agility. Kinaxis will enhance Cardinal Health's medical supply chain through concurrent planning and end-to-end network visibility and transparency while factoring in seasonality and pandemic planning; instantly balance demand and supply while accounting for capacity safeguards; and simulate product supply scenarios in seconds to create best-fit solutions for customers.

Cardinal Health partners with Kinaxis to optimize digital supply chain planning

DUBLIN, Ohio , Feb. 7, 2022 /PRNewswire/ -- Today Cardinal Health published its 2022 Biosimilars Report: The U.S. Journey and Path Ahead, a publication that brings together the latest industry data on biosimilar utilization and payer coverage with survey data from healthcare providers, and views from leading physicians and experts on biosimilars. The report delivers robust data and insights on where biosimilar adoption stands today in the U.S. and what is expected in 2022 and beyond as biosimilars come to market in key disease categories such as diabetes and immunology.

Cardinal Health Predicts 2022 to be Turning Point for Biosimilars in the U.S.

CAH has had a rough go the past few years with the opioid epidemic and coronavirus pandemic impacting their bottom line. Profit margins leave much to be desired and need to improve. Investors can expect a conservative total return CAGR of 14.7% over 5 years.

Cardinal Health: Call The Doctor, Share Buybacks Have Me Swooning

Cardinal Health's (CAH) fiscal second-quarter results benefit from a solid performance in the Pharmaceutical segment.

News for Cardinal Health Stock (CAH)